The effects of vildagliptin on glycemic variability in patients with type 2 diabetes on premixed insulin therapy
AimPatients on premixed insulin therapy usually have poor glycemic control. This study aimed to investigate the effect of vildagliptin in these patients.MethodsThis real-world study included patients with type 2 diabetes mellitus (T2DM), who were poorly glycemic controlled on premixed insulin therap...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-06-01
|
| Series: | Frontiers in Endocrinology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fendo.2025.1508918/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849689335789518848 |
|---|---|
| author | Deyue Kong Ziyang Shen Lanlan Jiang Xiaojing Xie Rengna Yan Ting Jing Yun Hu Jianhua Ma |
| author_facet | Deyue Kong Ziyang Shen Lanlan Jiang Xiaojing Xie Rengna Yan Ting Jing Yun Hu Jianhua Ma |
| author_sort | Deyue Kong |
| collection | DOAJ |
| description | AimPatients on premixed insulin therapy usually have poor glycemic control. This study aimed to investigate the effect of vildagliptin in these patients.MethodsThis real-world study included patients with type 2 diabetes mellitus (T2DM), who were poorly glycemic controlled on premixed insulin therapy and were subsequently added vildagliptin. The control group consisted of patients who only had their insulin doses adjusted without adding vildagliptin, matched for age, diabetic duration, HbA1c, and BMI. All patients underwent FGM, glycated hemoglobin(HbA1c), and glycated albumin(GA) measurements at baseline and three months after the treatment adjustment.ResultsPatients receiving vildagliptin treatment demonstrated significant reductions in HbA1c and GA levels (P<0.001 and P=0.009, respectively). The vildagliptin group exhibited a remarkable decrease in the mean amplitude of glycemic excursion (MAGE) (8.58 ± 0.36 vs. 6.62 ± 0.47, P<0.001), along with notable reductions in mean blood glucose (MBG) (10.7 ± 0.34 vs. 8.82 ± 0.39, P<0.001) and time above the target range (TAR) (52.60 ± 3.44 vs. 31.59 ± 4.31, P<0.001) compared to the control group. Moreover, there were notable improvements in the duration spent within the target range (TIR) (45.64 ± 3.33 vs. 64.22 ± 4.00, P<0.001), along with increases in the areas under the curve (AUC) for blood glucose levels above 4.4 (426.82 ± 83.19 vs. 892.16 ± 185.27, P=0.018) and 3.9 (213.81 ± 47.20 vs. 454.77 ± 103.21, P=0.029). Hourly mean blood glucose levels over a 2-week period monitored by FGM indicated lower blood glucose levels in the vildagliptin group, particularly after dinner (P=0.022).ConclusionVildagliptin added to premixed insulin effectively lowers blood glucose levels and reduces glycemic variability in patients with type 2 diabetes mellitus.Clinical Trial Registrationhttps://clinicaltrials.gov, identifier NCT04847219. |
| format | Article |
| id | doaj-art-9f98de7e52034160a7586ca75ff5a070 |
| institution | DOAJ |
| issn | 1664-2392 |
| language | English |
| publishDate | 2025-06-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Endocrinology |
| spelling | doaj-art-9f98de7e52034160a7586ca75ff5a0702025-08-20T03:21:40ZengFrontiers Media S.A.Frontiers in Endocrinology1664-23922025-06-011610.3389/fendo.2025.15089181508918The effects of vildagliptin on glycemic variability in patients with type 2 diabetes on premixed insulin therapyDeyue Kong0Ziyang Shen1Lanlan Jiang2Xiaojing Xie3Rengna Yan4Ting Jing5Yun Hu6Jianhua Ma7Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing, ChinaDepartment of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing, ChinaDepartment of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing, ChinaDepartment of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing, ChinaDepartment of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing, ChinaDepartment of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing, ChinaDepartment of Endocrinology, the Affiliated Wuxi People’s Hospital of Nanjing Medical University, Wuxi People’s Hospital, Wuxi Medical Center, Nanjing Medical University, Wuxi, ChinaDepartment of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing, ChinaAimPatients on premixed insulin therapy usually have poor glycemic control. This study aimed to investigate the effect of vildagliptin in these patients.MethodsThis real-world study included patients with type 2 diabetes mellitus (T2DM), who were poorly glycemic controlled on premixed insulin therapy and were subsequently added vildagliptin. The control group consisted of patients who only had their insulin doses adjusted without adding vildagliptin, matched for age, diabetic duration, HbA1c, and BMI. All patients underwent FGM, glycated hemoglobin(HbA1c), and glycated albumin(GA) measurements at baseline and three months after the treatment adjustment.ResultsPatients receiving vildagliptin treatment demonstrated significant reductions in HbA1c and GA levels (P<0.001 and P=0.009, respectively). The vildagliptin group exhibited a remarkable decrease in the mean amplitude of glycemic excursion (MAGE) (8.58 ± 0.36 vs. 6.62 ± 0.47, P<0.001), along with notable reductions in mean blood glucose (MBG) (10.7 ± 0.34 vs. 8.82 ± 0.39, P<0.001) and time above the target range (TAR) (52.60 ± 3.44 vs. 31.59 ± 4.31, P<0.001) compared to the control group. Moreover, there were notable improvements in the duration spent within the target range (TIR) (45.64 ± 3.33 vs. 64.22 ± 4.00, P<0.001), along with increases in the areas under the curve (AUC) for blood glucose levels above 4.4 (426.82 ± 83.19 vs. 892.16 ± 185.27, P=0.018) and 3.9 (213.81 ± 47.20 vs. 454.77 ± 103.21, P=0.029). Hourly mean blood glucose levels over a 2-week period monitored by FGM indicated lower blood glucose levels in the vildagliptin group, particularly after dinner (P=0.022).ConclusionVildagliptin added to premixed insulin effectively lowers blood glucose levels and reduces glycemic variability in patients with type 2 diabetes mellitus.Clinical Trial Registrationhttps://clinicaltrials.gov, identifier NCT04847219.https://www.frontiersin.org/articles/10.3389/fendo.2025.1508918/fullvildagliptintype 2 diabetes mellitusglycemic excursionflash glucose monitoringpremixed insulin |
| spellingShingle | Deyue Kong Ziyang Shen Lanlan Jiang Xiaojing Xie Rengna Yan Ting Jing Yun Hu Jianhua Ma The effects of vildagliptin on glycemic variability in patients with type 2 diabetes on premixed insulin therapy Frontiers in Endocrinology vildagliptin type 2 diabetes mellitus glycemic excursion flash glucose monitoring premixed insulin |
| title | The effects of vildagliptin on glycemic variability in patients with type 2 diabetes on premixed insulin therapy |
| title_full | The effects of vildagliptin on glycemic variability in patients with type 2 diabetes on premixed insulin therapy |
| title_fullStr | The effects of vildagliptin on glycemic variability in patients with type 2 diabetes on premixed insulin therapy |
| title_full_unstemmed | The effects of vildagliptin on glycemic variability in patients with type 2 diabetes on premixed insulin therapy |
| title_short | The effects of vildagliptin on glycemic variability in patients with type 2 diabetes on premixed insulin therapy |
| title_sort | effects of vildagliptin on glycemic variability in patients with type 2 diabetes on premixed insulin therapy |
| topic | vildagliptin type 2 diabetes mellitus glycemic excursion flash glucose monitoring premixed insulin |
| url | https://www.frontiersin.org/articles/10.3389/fendo.2025.1508918/full |
| work_keys_str_mv | AT deyuekong theeffectsofvildagliptinonglycemicvariabilityinpatientswithtype2diabetesonpremixedinsulintherapy AT ziyangshen theeffectsofvildagliptinonglycemicvariabilityinpatientswithtype2diabetesonpremixedinsulintherapy AT lanlanjiang theeffectsofvildagliptinonglycemicvariabilityinpatientswithtype2diabetesonpremixedinsulintherapy AT xiaojingxie theeffectsofvildagliptinonglycemicvariabilityinpatientswithtype2diabetesonpremixedinsulintherapy AT rengnayan theeffectsofvildagliptinonglycemicvariabilityinpatientswithtype2diabetesonpremixedinsulintherapy AT tingjing theeffectsofvildagliptinonglycemicvariabilityinpatientswithtype2diabetesonpremixedinsulintherapy AT yunhu theeffectsofvildagliptinonglycemicvariabilityinpatientswithtype2diabetesonpremixedinsulintherapy AT jianhuama theeffectsofvildagliptinonglycemicvariabilityinpatientswithtype2diabetesonpremixedinsulintherapy AT deyuekong effectsofvildagliptinonglycemicvariabilityinpatientswithtype2diabetesonpremixedinsulintherapy AT ziyangshen effectsofvildagliptinonglycemicvariabilityinpatientswithtype2diabetesonpremixedinsulintherapy AT lanlanjiang effectsofvildagliptinonglycemicvariabilityinpatientswithtype2diabetesonpremixedinsulintherapy AT xiaojingxie effectsofvildagliptinonglycemicvariabilityinpatientswithtype2diabetesonpremixedinsulintherapy AT rengnayan effectsofvildagliptinonglycemicvariabilityinpatientswithtype2diabetesonpremixedinsulintherapy AT tingjing effectsofvildagliptinonglycemicvariabilityinpatientswithtype2diabetesonpremixedinsulintherapy AT yunhu effectsofvildagliptinonglycemicvariabilityinpatientswithtype2diabetesonpremixedinsulintherapy AT jianhuama effectsofvildagliptinonglycemicvariabilityinpatientswithtype2diabetesonpremixedinsulintherapy |